Roksigeksal - antibacterial medication from the pharmaceutical macrolide for the treatment of infectious and inflammatory diseases.
Structure and Composition
According Roksigeksal instructions issued in the form of tablets, coated at 50, 150 and 300 mg. The active ingredient - Roxithromycin. Also, the product contains the following auxiliary components - povidone, poloxamer, microcrystalline cellulose, magnesium stearate, isopropyl alcohol, water, titanium dioxide, hydroxypropyl methylcellulose, PEG.
Externally Roksigeksal a tablet of round or oblong shape with a smooth surface. Produced the drug in the blisters of 10 tablets. In a cardboard box with 1 or 2 blisters with instruction.
Pharmacological action Roksigeksala
According to the instructions Roksigeksal is a semi-synthetic antibacterial drug macrolide.
To this drug-sensitive microorganisms as follows: pertussis bacillus, Borrelia, Campylobacter pylori, Campylobacter eyuni, chlamydia, clostridia, enterococci, gardenerella vaginal, staphylococci, streptococci, Legionella, helicobacter pylori, peptostreptokokki.
After oral administration, the drug is rapidly absorbed. The body is partially metabolized. Receiving Roksigeksala 12 hours provides effective preservation of drug concentrations in serum for one day. Roksigeksal penetrates well into different tissues (especially the palatine tonsil, lung, prostate).
Through the blood-brain barrier Roksigeksal hardly penetrates. The drug (less than 0, 05%) passes into breast milk. Write mainly intestine (50%) and kidneys (10%), lungs (15%).
According to the instructions shown in the following Roksigeksal infectious - inflammatory diseases:
- infections of the skin and soft tissues;
- respiratory tract infections (pharyngitis, sinusitis, tonsillitis, bronchitis, pneumonia);
- infections of the genitourinary system (except for gonococcal infections origin).
- hypersensitivity to the ingredients of the drug, as well as to macrolides in history;
- concomitant use of drugs that are derivatives of ergotamine and dihydroergotamine;
- pregnancy and lactation;
- age up to 2 months.
Precautions Roksigeksal appointed with symptoms of liver failure.
Dosing and Administration
According to the instructions Roksigeksala dose depends on body weight, severity of disease and the type of pathogen.
According to the instructions Roksigeksal should be taken as a whole, about 15 minutes before meals with water.
For adults, the usual daily dosage of the drug is 300 mg per day (150 mg, 2 times a day). If necessary, doctor daily dose may be increased to 600 mg per day. The duration of treatment depends on the severity Roksigeksalom diseases and microbial activity. Respiratory diseases treatment duration is usually 7-10 days, in chronic osteomyelitis - up to 2 months.
For children under 40 kg the usual daily dose is calculated from the formula 5-8 mg / kg body weight. Roksigeksalom course of treatment should not exceed 10 days.
Children weighing 7 to 13 kg is given 25 mg (1/2 tablet 50 mg), 2 times a day.
For children weighing 14 to 26 kg is given by 50 mg (1 tablet) formulation 2 times per day.
For children weighing 27 to 40 kg assigned 100 mg (2 tablets of 50 mg), 2 times a day.
For children weighing more than 40 kg Roksigeksala recommended daily dose is 300 mg per day (150 mg, 2 times a day).
Side effects Roksigeksala
According to reviews Roksigeksal rarely causes side effects. May cause nausea, vomiting, loss of appetite, abdominal pain, stool disorders, flatulence, headache, paresthesia, tinnitus, blurred vision and smell. Can also be observed in the form of laboratory abnormalities transaminase elevations in serum, increased levels of alkaline phosphatase, creatinine.
In the opinion of Roksigeksal rarely it causes allergic reactions (urticaria, bronchospasm, angioedema, eczema, anaphylactic shock).
In case of overdose may appear Roksigeksalom and increased side effects. Treatment is symptomatic (gastric lavage, the appointment of enterosorbents). The specific antidote is not found. Dialysis in overdose is not effective.
Interaction Roksigeksala with other drugs
Simultaneous administration with ergotamine and ergotaminopodobnymi drugs is contraindicated because of the risk of ergotism (spasm of blood vessels up to the limb necrosis).
Roksigeksal increases absorption of digoxin and other cardiac glycosides.
This drug reduces the therapeutic effect of indirect anticoagulants.
When concomitantly with theophylline increases the side effects of the latter.
Roksigeksal increases serum concentration astemizole, cisapride and pimozide, which may cause a prolonged QT interval, and contribute to arrhythmia.
The interaction with antacids, H2 blockers and karbmazepinom missing.
Roksigeksal should be used with caution in patients with hepatic insufficiency.
Note that the formulation has a cross resistance to erythromycin.
As with other antibacterial agents receiving, in the case of long-term use Roksigeksala may develop fungal infections.
If a patient during therapy Roksigeksalom prolonged diarrhea occurs, and there is a suspicion of pseudomembranous colitis, the drug should be discontinued.
Roksigeksal caution should be used in patients over 65 years of age may require adjustment of dosage.
Roksigeksala analogues are the following drugs: brilid, Remora, rokseptin, hydroxide, roksilor, roksimizan, roxithromycin, rulid, rulitsin, elroks. Before replacing analogue Roksigeksala should consult a doctor.